Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Anna-Larissa N. Niemeijer"'
Autor:
Rieneke van de Ven, Anna-Larissa N. Niemeijer, Anita G.M. Stam, Sayed M.S. Hashemi, Christian G. Slockers, Johannes M. Daniels, Erik Thunnissen, Egbert F. Smit, Tanja D. de Gruijl, Adrianus J. de Langen
Publikováno v:
ERJ Open Research, Vol 3, Iss 2 (2017)
The treatment of advanced nonsmall cell lung cancer (NSCLC) with PD-1/PD-L1 immune checkpoint inhibitors has improved clinical outcome for a proportion of patients. The current challenge is to find better biomarkers than PD-L1 immunohistochemistry (I
Externí odkaz:
https://doaj.org/article/f517653436f94dd583a82eca4c0efaaa
Autor:
Egbert F. Smit, Joachim G. Aerts, Heinrich Roder, Carlos Oliveira, Joanna Roder, Kim Monkhorst, Anna-Larissa N. Niemeijer, Daan P. Hurkmans, Karlijn Hummelink, Mirte Muller
Purpose:Pretreatment selection of patients with non–small cell lung cancer (NSCLC) who would derive clinical benefit from treatment with immune checkpoint inhibitors (CPIs) would fulfill an unmet clinical need by reducing unnecessary toxicities fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdb5716c144eea6215003dd5cfd9e49b
https://doi.org/10.1158/1078-0432.c.6529436.v1
https://doi.org/10.1158/1078-0432.c.6529436.v1
Autor:
Adrianus J. de Langen, Danielle J. Vugts, Guus A.M.S. van Dongen, Berlinda J. de Wit–van der Veen, Otto S. Hoekstra, Egbert F. Smit, Frank Johannes Borm, Daniela E. Oprea-Lager, Erik Thunnissen, Ronald Boellaard, Anna-Larissa N. Niemeijer, Jasper Smit, Marc C. Huisman
Publikováno v:
Journal of Nuclear Medicine, 63(5), 686-693. Society of Nuclear Medicine Inc.
Smit, J, Borm, F J, Niemeijer, A-L N, Huisman, M C, Hoekstra, O S, Boellaard, R, Oprea-Lager, D E, Vugts, D J, van Dongen, G A M S, de Wit-van der Veen, B J, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of Nuclear Medicine, vol. 63, no. 5, pp. 686-693 . https://doi.org/10.2967/jnumed.121.262473
Journal of Nuclear Medicine, 63(5), 686-693. SOC NUCLEAR MEDICINE INC
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(5), 686-693
Smit, J, Borm, F J, Niemeijer, A-L N, Huisman, M C, Hoekstra, O S, Boellaard, R, Oprea-Lager, D E, Vugts, D J, van Dongen, G A M S, de Wit-van der Veen, B J, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of Nuclear Medicine, vol. 63, no. 5, pp. 686-693 . https://doi.org/10.2967/jnumed.121.262473
Journal of Nuclear Medicine, 63(5), 686-693. SOC NUCLEAR MEDICINE INC
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(5), 686-693
Background: Better biomarkers are needed to predict treatment outcome in NSCLC patients treated with anti PD-(L)1 checkpoint inhibitors. PD-L1 immunohistochemistry has limited predictive value, possibly due to tumor heterogeneity of PD-L1 expression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4edad85d4f4c7776c62955765b913c
https://research.vumc.nl/en/publications/66be6300-ca81-41b8-bdaa-5834514ee6c6
https://research.vumc.nl/en/publications/66be6300-ca81-41b8-bdaa-5834514ee6c6
Autor:
Otto S. Hoekstra, Egbert F. Smit, Guus A.M.S. van Dongen, Berlinda van de Veen, Adrianus J. de Langen, Idris Bahce, Marc C. Huisman, Danielle J. Vugts, Daniela E Oprea Lager, Anna-Larissa N. Niemeijer, Ronald Boellaard, Erik Thunnissen
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(3), 362-367
Niemeijer, A-L N, Oprea-Lager, D E, Huisman, M C, Hoekstra, O S, Boellaard, R, de Wit-van der Veen, B J, Bahce, I, Vugts, D J, van Dongen, G A M S, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' Study of 89 Zr-Pembrolizumab PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3, pp. 362-367 . https://doi.org/10.2967/jnumed.121.261926, https://doi.org/10.2967/jnumed.121.261926
Niemeijer, A-L N, Oprea-Lager, D E, Huisman, M C, Hoekstra, O S, Boellaard, R, de Wit-van der Veen, B J, Bahce, I, Vugts, D J, van Dongen, G A M S, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' Study of 89 Zr-Pembrolizumab PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3, pp. 362-367 . https://doi.org/10.2967/jnumed.121.261926, https://doi.org/10.2967/jnumed.121.261926
The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for selecting non-small cell lung cancer (NSCLC) patients for single-agent treatment with pembrolizumab, a programmed cell death 1 (PD-1) monoclonal antibody. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7970527de6db97efc4e9880e2ecbf4d2
https://research.vumc.nl/en/publications/70b0c9bc-4154-4c9f-8dbc-74fde31746fd
https://research.vumc.nl/en/publications/70b0c9bc-4154-4c9f-8dbc-74fde31746fd
Autor:
Anna Larissa N. Niemeijer, Sara Sahba, Adrianus J. de Langen, Egbert F. Smit, Birgit I. Lissenberg-Witte, Erik Thunnissen
Publikováno v:
British Journal of Cancer, 123(3), 392-402. SPRINGERNATURE
Niemeijer, A L N, Sahba, S, Smit, E F, Lissenberg-Witte, B I, de Langen, A J & Thunnissen, E 2020, ' Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy ', British Journal of Cancer, vol. 123, no. 3, pp. 392-402 . https://doi.org/10.1038/s41416-020-0888-5
British Journal of Cancer, 123(3), 392-402. Nature Publishing Group
British Journal of Cancer
Niemeijer, A L N, Sahba, S, Smit, E F, Lissenberg-Witte, B I, de Langen, A J & Thunnissen, E 2020, ' Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy ', British Journal of Cancer, vol. 123, no. 3, pp. 392-402 . https://doi.org/10.1038/s41416-020-0888-5
British Journal of Cancer, 123(3), 392-402. Nature Publishing Group
British Journal of Cancer
Background Immune checkpoint inhibitors are most beneficial in patients with high tumour PD-L1 expression. However, the use of PD-L1 expression is not straightforward. We investigated PD-L1 expression and immune cell (IC) infiltrates in non-small-cel
Autor:
Joanna Roder, Carlos R. Oliveira, Egbert F. Smit, Mirte Muller, Heinrich Roder, Kim Monkhorst, Anna-Larissa N. Niemeijer, Joachim G.J.V. Aerts, Karlijn Hummelink, Daan P. Hurkmans
Publikováno v:
Clinical Cancer Research, 26(19), 5188-5197. American Association for Cancer Research Inc.
Clinical Cancer Research, 26(19), 5188-5197. AMER ASSOC CANCER RESEARCH
Muller, M, Hummelink, K, Hurkmans, D P, Niemeijer, A-L N, Monkhorst, K, Roder, J, Oliveira, C, Roder, H, Aerts, J G & Smit, E F 2020, ' A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors ', Clinical Cancer Research, vol. 26, no. 19, pp. 5188-5197 . https://doi.org/10.1158/1078-0432.CCR-20-0538
Clinical Cancer Research, 26(19), 5188-5197. AMER ASSOC CANCER RESEARCH
Muller, M, Hummelink, K, Hurkmans, D P, Niemeijer, A-L N, Monkhorst, K, Roder, J, Oliveira, C, Roder, H, Aerts, J G & Smit, E F 2020, ' A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors ', Clinical Cancer Research, vol. 26, no. 19, pp. 5188-5197 . https://doi.org/10.1158/1078-0432.CCR-20-0538
Purpose: Pretreatment selection of patients with non–small cell lung cancer (NSCLC) who would derive clinical benefit from treatment with immune checkpoint inhibitors (CPIs) would fulfill an unmet clinical need by reducing unnecessary toxicities fr
Autor:
Ferdinandos Skoulidis, George R. Simon, Idris Bahce, Paul Baas, Joachim G.J.V. Aerts, Quynh Nhu Nguyen, Anna Larissa N. Niemeijer, Steven H. Lin, Dawei Chen, Kewen He, Heike Peulen, Brian P. Hobbs, Roshal R. Patel, Vivek Verma, James W. Welsh, Willemijn S. M. E. Theelen, Joe Y. Chang, John V. Heymach, Patricia M. de Groot, Nathan Comeaux
Publikováno v:
The Lancet Respiratory Medicine, 9(5), 467-475. Elsevier Limited
The Lancet Respiratory Medicine, 9(5), 467-475. Elsevier Ltd.
Theelen, W S M E, Chen, D, Verma, V, Hobbs, B P, Peulen, H M U, Aerts, J G J V, Bahce, I, Niemeijer, A L N, Chang, J Y, de Groot, P M, Nguyen, Q-N, Comeaux, N I, Simon, G R, Skoulidis, F, Lin, S H, He, K, Patel, R, Heymach, J, Baas, P & Welsh, J W 2021, ' Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials ', The Lancet Respiratory Medicine, vol. 9, no. 5, pp. 467-475 . https://doi.org/10.1016/S2213-2600(20)30391-X
The Lancet Respiratory Medicine, 9(5), 467-475. ELSEVIER SCI LTD
The Lancet Respiratory Medicine, 9(5), 467-475. Elsevier Ltd.
Theelen, W S M E, Chen, D, Verma, V, Hobbs, B P, Peulen, H M U, Aerts, J G J V, Bahce, I, Niemeijer, A L N, Chang, J Y, de Groot, P M, Nguyen, Q-N, Comeaux, N I, Simon, G R, Skoulidis, F, Lin, S H, He, K, Patel, R, Heymach, J, Baas, P & Welsh, J W 2021, ' Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials ', The Lancet Respiratory Medicine, vol. 9, no. 5, pp. 467-475 . https://doi.org/10.1016/S2213-2600(20)30391-X
The Lancet Respiratory Medicine, 9(5), 467-475. ELSEVIER SCI LTD
Findings Overall, 148 patients were included in the pooled analysis, 76 of whom had been assigned pembrolizumab and 72 who had been assigned pembrolizumab plus radiotherapy. Median follow-up for all patients was 33 months (IQR 32?4?33?6). 124 (84%) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcdadd3a2e31d7df46de6d2585dcdbe9
https://research.vumc.nl/en/publications/56927a12-23a7-4f97-a281-de8001690bb8
https://research.vumc.nl/en/publications/56927a12-23a7-4f97-a281-de8001690bb8
Autor:
Ferry Lalezari, Jeltje F. de Vries, Paul Baas, Kim Monkhorst, Willemijn S. M. E. Theelen, Adrianus J. de Langen, Heike Peulen, Anna-Larissa N. Niemeijer, Daphne W. Dumoulin, Vincent van der Noort, Idris Bahce, Joachim G.J.V. Aerts
Publikováno v:
Theelen, W S M E, Peulen, H M U, Lalezari, F, van der Noort, V, de Vries, J F, Aerts, J G J V, Dumoulin, D W, Bahce, I, Niemeijer, A-L N, de Langen, A J, Monkhorst, K & Baas, P 2019, ' Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial ', JAMA Oncology, vol. 5, no. 9, pp. 1276-1282 . https://doi.org/10.1001/jamaoncol.2019.1478
JAMA Oncology, 5(9), 1276-1282. American Medical Association
JAMA Oncol
JAMA Oncology, 5(9), 1276-1282. American Medical Association
JAMA Oncol
Importance: Many patients with advanced non-small cell lung cancer (NSCLC) receiving immunotherapy show primary resistance. High-dose radiotherapy can lead to increased tumor antigen release, improved antigen presentation, and T-cell infiltration. Th
Autor:
Dasa Lipovsek, Idris Bahce, N.H. Hendrikse, Danielle J. Vugts, G.A.M.S. (Guus) van Dongen, Alex J. Poot, Anna-Larissa N. Niemeijer, Egbert F. Smit, T.D. de Gruijl, Marc C. Huisman, Ronald Boellaard, David J. Donnelly, Ralph Adam Smith, Erik Thunnissen, Wendy Hayes, Linda M. Velasquez, David Leung, Albert D. Windhorst, Shuyan Du, A.J. de Langen, Samuel J. Bonacorsi, Otto S. Hoekstra, Paul E. Morin
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-5 (2018)
Niemeijer, A N, Leung, D, Huisman, M C, Bahce, I, Hoekstra, O S, van Dongen, G A M S, Boellaard, R, Du, S, Hayes, W, Smith, R, Windhorst, A D, Hendrikse, N H, Poot, A, Vugts, D J, Thunnissen, E, Morin, P, Lipovsek, D, Donnelly, D J, Bonacorsi, S J, Velasquez, L M, de Gruijl, T D, Smit, E F & de Langen, A J 2018, ' Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer ', Nature Communications, vol. 9, no. 1, 4664 . https://doi.org/10.1038/s41467-018-07131-y
Nature Communications
Nature Communications, 9(1):4664. Nature Publishing Group UK
Niemeijer, A N, Leung, D, Huisman, M C, Bahce, I, Hoekstra, O S, van Dongen, G A M S, Boellaard, R, Du, S, Hayes, W, Smith, R, Windhorst, A D, Hendrikse, N H, Poot, A, Vugts, D J, Thunnissen, E, Morin, P, Lipovsek, D, Donnelly, D J, Bonacorsi, S J, Velasquez, L M, de Gruijl, T D, Smit, E F & de Langen, A J 2018, ' Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer ', Nature Communications, vol. 9, no. 1, 4664 . https://doi.org/10.1038/s41467-018-07131-y
Nature Communications
Nature Communications, 9(1):4664. Nature Publishing Group UK
PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive value of small biopsies. Here we show that tumor PD-L1 and PD-1 expressi
Autor:
Anna-Larissa N, Niemeijer, Daniela E, Oprea-Lager, Marc C, Huisman, Otto S, Hoekstra, Ronald, Boellaard, Berlinda J, de Wit-van der Veen, Idris, Bahce, Daniëlle J, Vugts, Guus A M S, van Dongen, Erik, Thunnissen, Egbert F, Smit, Adrianus J, de Langen
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 63(3)
The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for selecting non-small cell lung cancer (NSCLC) patients for single-agent treatment with pembrolizumab, a programmed cell death 1 (PD-1) monoclonal antibody. However,